Tumor Biology

, Volume 34, Issue 2, pp 821–825 | Cite as

Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer

  • Kai-Yu Han
  • Xin Gu
  • Hao-Ran Wang
  • Dong Liu
  • Fu-Zhen Lv
  • Jia-Ning Li
Research Article

Abstract

The aim of this study was to detect MAC30 expression in human non-small cell lung cancer (NSCLC) and to analyze its association with prognosis of NSCLC patients. Quantitative real-time RT-PCR was performed to examine the expression of MAC30 mRNA in 20 cases of NSCLC and corresponding non-tumor tissue samples. Immunohistochemistry was performed to detect the expression of MAC30 in 95 NSCLC tissues. We found that the expression levels of MAC30 mRNA in NSCLC tissues were significantly higher than those in corresponding non-tumor tissues. High-level MAC30 expression was correlated with poor tumor differentiation, TNM stage, and lymph node metastasis. Patients with high expression levels of MAC30 showed lower overall survival rate than those with low expression levels. Multivariate analysis showed that high MAC30 protein expression was an independent prognostic factor for NSCLC patients. Our study suggests that over-expression of MAC30 may play an important role in the progression of NSCLC and MAC30 expression may offer a valuable marker for predicting the outcome of patients with NSCLC.

Keywords

MAC30 NSCLC Biomarker Prognosis 

Notes

Acknowledgments

This work was funded by research grants from Project of Education Department of Heilongjiang Province (no. 12521z021 and 11521096), China

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. doi: 10.3322/CA.2007.0010.PubMedCrossRefGoogle Scholar
  2. 2.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50. doi: 10.1200/JCO.2005.05.2308.PubMedCrossRefGoogle Scholar
  3. 3.
    Murphy M, Pykett MJ, Harnish P, Zang KD, George DL. Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ. 1993;4:715–22.PubMedGoogle Scholar
  4. 4.
    Malhotra K, Luehrsen KR, Costello LL, Raich TJ, Sim K, Foltz L, et al. Identification of differentially expressed mRNAs in human fetal liver across gestation. Nucleic Acids Res. 1999;27:839–47.PubMedCrossRefGoogle Scholar
  5. 5.
    Kayed H, Kleeff J, Ding J, Hammer J, Giese T, Zentgraf H, et al. Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract. Histol Histopathol. 2004;19:1021–31.PubMedGoogle Scholar
  6. 6.
    Potapova O, Anisimov SV, Gorospe M, Dougherty RH, Gaarde WA, Boheler KR, et al. Targets of c-Jun NH(2)-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression. Cancer Res. 2002;62:3257–63.PubMedGoogle Scholar
  7. 7.
    Sobin LH, Fleming ID. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. TNM classification of malignant tumors, fifth edition. Cancer. 1997;80:1803–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8.PubMedGoogle Scholar
  10. 10.
    Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Xiao M, Li H, Yang S, Huang Y, Jia S, Wang H, et al. Expression of MAC30 protein is related to survival and clinicopathological variables in breast cancer. J Surg Oncol. 2012. doi: 10.1002/jso.23269.
  12. 12.
    Zhao ZR, Zhang LJ, He XQ, Zhang ZY, Zhang F, Li F, et al. Significance of mRNA and protein expression of MAC30 in progression of colorectal cancer. Chemotherapy. 2011;57:394–401.PubMedCrossRefGoogle Scholar
  13. 13.
    Yan BY, Wang DW, Zhu ZL, Yang YH, Wang MW, Cui DS, et al. Overexpression of MAC30 in the cytoplasm of oral squamous cell carcinoma predicts nodal metastasis and poor differentiation. Chemotherapy. 2010;56(6):424–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhang ZY, Zhao ZR, Adell G, Jarlsfelt I, Cui YX, Kayed H, et al. Expression of MAC30 in rectal cancers with or without preoperative radiotherapy. Oncology. 2006;71:259–65.PubMedCrossRefGoogle Scholar
  15. 15.
    Moparthi SB, Arbman G, Wallin A, Kayed H, Kleeff J, Zentgraf H, et al. Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. Int J Oncol. 2007;30(1):91–5.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Kai-Yu Han
    • 1
  • Xin Gu
    • 2
  • Hao-Ran Wang
    • 3
  • Dong Liu
    • 4
  • Fu-Zhen Lv
    • 1
  • Jia-Ning Li
    • 1
  1. 1.Department of Respiratory MedicineThe Second Affiliated Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Department of Head and Neck SurgeryThe Third Affiliated Hospital of Harbin Medical UniversityHarbinChina
  3. 3.Department of Internal MedicineThe fourth hospital of Heilongjiang ProvinceHarbinChina
  4. 4.Department of General SurgeryThe fourth hospital of Heilongjiang ProvinceHarbinChina

Personalised recommendations